Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100545
Jinghao Nicholas Ngiam , Thuan Tong Tan , Ban Hock Tan , Wenlu Hou , Aloysius Yew Leng Ho , Jeffrey Kim Siang Quek , Yeh Ching Linn , Francesca Lorraine Wei Inng Lim , Hein Than , Shimin Jasmine Chung
Toxoplasmosis is a rare but potentially fatal complication post-allogeneic hematopoietic stem cell transplantation (HSCT), often due to latent reactivation. In Singapore, low seroprevalence limits routine screening and prophylaxis. We report the first reported case of disseminated toxoplasmosis following HSCT in Singapore. A 58-year-old woman with fever and altered mental status two months post-transplant. She had pancytopenia, acute kidney injury, and pneumonitis, with non-specific brain MRI findings. Toxoplasma polymerase chain reaction from serum, bone marrow, and cerebrospinal fluid was positive. Despite treatment with trimethoprim-sulfamethoxazole, pyrimethamine, and sulfadiazine, she developed seizures, intracranial haemorrhage, and nosocomial infections, ultimately succumbing one month later. This case potentially highlights the consideration of routine pre-transplant Toxoplasma screening and prevention strategies, even in regions with low seroprevalence.
{"title":"Fatal case of disseminated toxoplasmosis following allogeneic stem cell transplantation in Singapore – a case report and review of literature","authors":"Jinghao Nicholas Ngiam , Thuan Tong Tan , Ban Hock Tan , Wenlu Hou , Aloysius Yew Leng Ho , Jeffrey Kim Siang Quek , Yeh Ching Linn , Francesca Lorraine Wei Inng Lim , Hein Than , Shimin Jasmine Chung","doi":"10.1016/j.lrr.2025.100545","DOIUrl":"10.1016/j.lrr.2025.100545","url":null,"abstract":"<div><div>Toxoplasmosis is a rare but potentially fatal complication post-allogeneic hematopoietic stem cell transplantation (HSCT), often due to latent reactivation. In Singapore, low seroprevalence limits routine screening and prophylaxis. We report the first reported case of disseminated toxoplasmosis following HSCT in Singapore. A 58-year-old woman with fever and altered mental status two months post-transplant. She had pancytopenia, acute kidney injury, and pneumonitis, with non-specific brain MRI findings. Toxoplasma polymerase chain reaction from serum, bone marrow, and cerebrospinal fluid was positive. Despite treatment with trimethoprim-sulfamethoxazole, pyrimethamine, and sulfadiazine, she developed seizures, intracranial haemorrhage, and nosocomial infections, ultimately succumbing one month later. This case potentially highlights the consideration of routine pre-transplant Toxoplasma screening and prevention strategies, even in regions with low seroprevalence.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"24 ","pages":"Article 100545"},"PeriodicalIF":0.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145094823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2024.100498
V Da Silva Constante , H Couvert , A Wolfromm , M Ilzkovitz
We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified, represents 25 % of all peripheral T-cell lymphoma. Its diagnosis remains challenging due to the polymorphous clinical presentation and pathological heterogeneity. Myelofibrosis associated with malignant lymphomas is rare and peripheral T-cell lymphoma is even rarer. To our knowledge, this is the first case to describe an association between May-Hegglin syndrome and a peripheral T-cell lymphoma.
{"title":"When the mask slips: A peripheral T-cell lymphoma disguised as lupus with myelofibrosis in a patient with May-Hegglin syndrome","authors":"V Da Silva Constante , H Couvert , A Wolfromm , M Ilzkovitz","doi":"10.1016/j.lrr.2024.100498","DOIUrl":"10.1016/j.lrr.2024.100498","url":null,"abstract":"<div><div>We describe the case of a female patient with May-Hegglin syndrome who developed peripheral T-cell lymphoma not otherwise specified. The patient presents with systemic lupus erythematous phenotype and myelofibrosis secondary to T-cell lymphoma. Peripheral T-cell lymphoma not otherwise specified, represents 25 % of all peripheral T-cell lymphoma. Its diagnosis remains challenging due to the polymorphous clinical presentation and pathological heterogeneity. Myelofibrosis associated with malignant lymphomas is rare and peripheral T-cell lymphoma is even rarer. To our knowledge, this is the first case to describe an association between May-Hegglin syndrome and a peripheral T-cell lymphoma.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100498"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100514
Ugur Calis , Merve Aydogan , Guldane Cengiz Seval , Klara Dalva , Selami Kocak Toprak
High expression of immune checkpoint markers may leukemic cells to evade the immune system in AML. This study aimed to investigate the relationship between PD-1/PD-L1 expression and treatment outcomes in AML patients.. The study included 21 patients and 18 healthy volunteers. Non-responders exhibited significantly higher PD-1 expression (MFI) in CD3+ and CD4+ T cells. At the time of diagnosis, bone marrow samples from patients exhibited a significantly higher proportion of PD-1 expression in CD3+, CD4+, and CD8+ T lymphocytes than peripheral blood samples. The results revealed an association between PD-1/PD-L1 expression and clinical traits in newly diagnosed AML patients.
{"title":"Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients","authors":"Ugur Calis , Merve Aydogan , Guldane Cengiz Seval , Klara Dalva , Selami Kocak Toprak","doi":"10.1016/j.lrr.2025.100514","DOIUrl":"10.1016/j.lrr.2025.100514","url":null,"abstract":"<div><div>High expression of immune checkpoint markers may leukemic cells to evade the immune system in AML. This study aimed to investigate the relationship between PD-1/PD-L1 expression and treatment outcomes in AML patients.. The study included 21 patients and 18 healthy volunteers. Non-responders exhibited significantly higher PD-1 expression (MFI) in CD3+ and CD4+ <em>T</em> cells. At the time of diagnosis, bone marrow samples from patients exhibited a significantly higher proportion of PD-1 expression in CD3+, CD4+, and CD8+ <em>T</em> lymphocytes than peripheral blood samples. The results revealed an association between PD-1/PD-L1 expression and clinical traits in newly diagnosed AML patients.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100514"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2024.100495
Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton
Objective
This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.
Summary
The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.
{"title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","authors":"Abdur Jamil , Zaheer Qureshi , Zain Mary El-amir , Gillian Kupakuwana-Suk , Hamzah Akram , Mohsin Ahmad , Eric Huselton","doi":"10.1016/j.lrr.2024.100495","DOIUrl":"10.1016/j.lrr.2024.100495","url":null,"abstract":"<div><h3>Objective</h3><div>This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways.</div></div><div><h3>Summary</h3><div>The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100495"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.lrr.2025.100503
Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY
{"title":"Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML","authors":"Taner TAN , Genco Gençdal , Ümit Barbaros Üre , Olga Meltem AKAY","doi":"10.1016/j.lrr.2025.100503","DOIUrl":"10.1016/j.lrr.2025.100503","url":null,"abstract":"","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"23 ","pages":"Article 100503"},"PeriodicalIF":0.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号